Annette Bakker

President at Children's Tumor Foundation

Annette Bakker

Annette Bakker

President at Children's Tumor Foundation

Overview
Career Highlights

Children's Tumor Foundation

RelSci Relationships

162

Number of Boards

1

Contact Data
Trying to get in touch with Annette Bakker? Subscribe today to access his professional contact information.
Relationships
RelSci Relationships are individuals Annette Bakker likely has professional access to. A relationship does not necessarily indicate a personal connection.

Vice President at Earle Associates

Relationship likelihood: Strong

NII Holdings, Inc.

Relationship likelihood: Strong

Co-Founder at Children's Tumor Foundation

Relationship likelihood: Strong

Former President, Indiana Chapter at Children's Tumor Foundation

Relationship likelihood: Strong

Former Director, Cupid's Undie Run Program at Children's Tumor Foundation

Relationship likelihood: Strong

President, Arkansas Chapter at Children's Tumor Foundation

Relationship likelihood: Strong

Former Group Senior Vice President at ROPER STARCH WORLDWIDE INC

Relationship likelihood: Strong

Former Professional at Galloway Promotions, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Lambda Legal Defense & Education Fund, Inc.

Relationship likelihood: Strong

Professional at Standard & Poor's Financial Services LLC,

Relationship likelihood: Strong

Paths to Annette Bakker
Potential Connections via
Relationship Science
You
Annette Bakker
President at Children's Tumor Foundation
Education
PhD in Biochemistry

UAntwerpen The University of Antwerp (Universiteit Antwerpen) is a young and dynamic Belgian university. It is characterised by its high standards in education, internationally competitive research and entrepreneurial approach. It was founded in 2003 after the merger of the three universities of Antwerp. The university's roots go back to 1852. The University of Antwerp has 9 faculties and several autonomous, faculty-like institutes. Doctoral programmes are available in all faculties, with more than 20,109 students (+1,479 PhD students) registered. In total the university has over 4.987 staff members. The University of Antwerp hosts 5 centres of excellence Nanostructures, Molecular Neurogenetics, Environmental Studies, Social Policy, Evaluation of Vaccination Education is student-centred and competency-based. Students are stimulated to develop into independently minded people who are capable of thinking analytically. The University of Antwerp has adopted the bachelor-master structure. It offers 3-year Bachelor programmes (180 ECTS credits) and 1-year or 2-year Master programmes (60 or 120 ECTS credits). The university is part of the Antwerp University Association (AUHA), a regional association with the university and 3university colleges for professional education.

Career History
President
2011 - Current

Founded in 1978, The Children’s Tumor Foundation is dedicated to improving the health and well being of more than 100,000 Americans living with neurofibromatosis (NF). Its research program has played a key role in the discovery of the genes that cause NF, understanding the biology of NF, creation of The NF Clinic Network and preclinical screening of promising drug compounds to treat NF.

Head, Oncology
Prior

Siena Biotech SpA develops and discovers drugs. The company was founded in 2000 and is headquartered in Siena, Italy.

Leader, Oncology Group
Prior

Janssen Pharmaceutica NV provides pharmaceutical research and manufactures related products. It provides research and development in human disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium.

Boards & Committees
Member, Board of Directors
Current

Founded in 1978, The Children’s Tumor Foundation is dedicated to improving the health and well being of more than 100,000 Americans living with neurofibromatosis (NF). Its research program has played a key role in the discovery of the genes that cause NF, understanding the biology of NF, creation of The NF Clinic Network and preclinical screening of promising drug compounds to treat NF.